lamotrigine has been researched along with Cardiovascular Diseases in 4 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to investigate risk factors for cardiovascular disease in patients with epilepsy using the new antiepileptic drug levetiracetam (LEV), compared with patients taking carbamazepine (CBZ) or lamotrigine (LTG)." | 7.76 | Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. ( Gjerstad, L; Luef, G; Mørkrid, L; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2010) |
| "The aim of the study was to investigate risk factors for cardiovascular disease in patients with epilepsy using the new antiepileptic drug levetiracetam (LEV), compared with patients taking carbamazepine (CBZ) or lamotrigine (LTG)." | 3.76 | Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. ( Gjerstad, L; Luef, G; Mørkrid, L; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2010) |
| "Although mania defines bipolar I disorder, depressive episodes and symptoms dominate the longitudinal course of, and disproportionately account for morbidity and mortality in, bipolar disorders." | 2.66 | Bipolar disorders. ( Berk, M; Brietzke, E; Goldstein, BI; Kessing, LV; López-Jaramillo, C; Majeed, A; Malhi, GS; Mansur, RB; McIntyre, RS; Nierenberg, AA; Rosenblat, JD; Vieta, E; Vinberg, M; Young, AH, 2020) |
| "Lamotrigine was intravenously administered in doses of 0." | 1.62 | Reverse translational analysis of clinically reported, lamotrigine-induced cardiovascular adverse events using the halothane-anesthetized dogs. ( Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Kawai, S; Matsumoto, A; Nunoi, Y; Sugiyama, A; Takei, Y, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Larsson, D | 1 |
| Baftiu, A | 1 |
| Johannessen Landmark, C | 1 |
| von Euler, M | 1 |
| Kumlien, E | 1 |
| Åsberg, S | 1 |
| Zelano, J | 1 |
| Goto, A | 1 |
| Hagiwara-Nagasawa, M | 1 |
| Kambayashi, R | 1 |
| Nunoi, Y | 1 |
| Izumi-Nakaseko, H | 1 |
| Kawai, S | 1 |
| Takei, Y | 1 |
| Matsumoto, A | 1 |
| Sugiyama, A | 1 |
| McIntyre, RS | 1 |
| Berk, M | 1 |
| Brietzke, E | 1 |
| Goldstein, BI | 1 |
| López-Jaramillo, C | 1 |
| Kessing, LV | 1 |
| Malhi, GS | 1 |
| Nierenberg, AA | 1 |
| Rosenblat, JD | 1 |
| Majeed, A | 1 |
| Vieta, E | 1 |
| Vinberg, M | 1 |
| Young, AH | 1 |
| Mansur, RB | 1 |
| Svalheim, S | 1 |
| Luef, G | 1 |
| Rauchenzauner, M | 1 |
| Mørkrid, L | 1 |
| Gjerstad, L | 1 |
| Taubøll, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levetiracetam, Carbamazepine and Lamotrigine and Hormonal Side Effects in Adult Males and Females.[NCT00460070] | 240 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for lamotrigine and Cardiovascular Diseases
| Article | Year |
|---|---|
Bipolar disorders.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; B | 2020 |
3 other studies available for lamotrigine and Cardiovascular Diseases
| Article | Year |
|---|---|
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Cohort Studies; Dr | 2022 |
Reverse translational analysis of clinically reported, lamotrigine-induced cardiovascular adverse events using the halothane-anesthetized dogs.
Topics: Anesthesia, General; Anesthetics, Inhalation; Animals; Cardiovascular Diseases; Disease Models, Anim | 2021 |
Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Comorbidity; Epilepsy; F | 2010 |